Key result
Higher LV sphericity linked to ~62% greater incident cardiomyopathy risk per SD.
Why the study?
The human heart possesses significant uncharacterized phenotypic variation beyond traditional metrics of size and function, and characterizing cardiac shape may improve the understanding and classification of cardiovascular risk.
Does increased left ventricular sphericity predict incident atrial fibrillation, cardiomyopathy, and heart failure in adults with normal LV size and systolic function?
Cohort (n=38,897)
Yes
Does increased left ventricular sphericity predict incident atrial fibrillation, cardiomyopathy, and heart failure in adults with normal LV size and systolic function?
Effect estimate: HR 1.62 (95% CI 1.29-2.02)
p-value: p=2.4x10-5
Increased left ventricular sphericity in individuals with normal heart size and function is an independent predictor of incident atrial fibrillation, cardiomyopathy, and heart failure, and shares genetic architecture with non-ischemic cardiomyopathy.
LV sphericity may flag higher AF, cardiomyopathy, and HF risk in preserved LV function; leaves open utility for risk stratification.
Quantification of chamber size and systolic function is a fundamental component of cardiac imaging, as these measurements provide a basis for establishing both diagnosis and appropriate treatment for a spectrum of cardiomyopathies. However, the human heart is a complex structure with significant uncharacterized phenotypic variation beyond traditional metrics of size and function. Characterizing variation in cardiac shape and morphology can add to our ability to understand and classify cardiovascular risk and pathophysiology. We describe deep learning enabled measurement of left ventricle (LV) sphericity using cardiac magnetic resonance imaging data from the UK Biobank and show that among adults with normal LV volumes and systolic function, increased sphericity is associated with increased risk for incident atrial fibrillation (HR 1.31 per SD, 95% CI 1.23-1.38), cardiomyopathy (HR 1.62 per SD, 95% CI 1.29-2.02), and heart failure (HR 1.24, 95% CI 1.11-1.39), independent of traditional risk factors including age, sex, hypertension, and body mass index. Using genome-wide association studies, we identify four loci associated with sphericity at genome-wide significance. These loci harbor known and suspected cardiomyopathy genes. Through genetic correlation and Mendelian randomization, we provide evidence that sphericity may represent a subclinical manifestation of non-ischemic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Vukadinovic et al. (2022) conducted a cohort in Normal left ventricular volume and systolic function (n=38,897). Left ventricle (LV) sphericity index was evaluated on Incident cardiomyopathy (HR 1.62, 95% CI 1.29-2.02, p=2.4x10-5). Among adults with normal left ventricular size and function, a 1-SD increase in left ventricular sphericity was associated with a 62% increased risk of incident cardiomyopathy (HR 1.62).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: